Search | IOVS | ARVO Journals

View

Showing 1 – 7 of 7

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2017

RVO cross trial comparison: six-month outcomes in anti-VEGF-treated patients with branch and central retinal vein occlusion

Nikolas JS London; Pin-wen Wang; Avanti Ghanekar; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4623. doi:

ARVO Annual Meeting Abstract June 2017

Branch and central retinal vein occlusion: clinical pearls from trials of ranibizumab

Mimi Liu; David Eichenbaum; Sarah Taylor; Pin-wen Wang; Carlos Quezada-Ruiz

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4624. doi:

ARVO Annual Meeting Abstract September 2016

Individualized ranibizumab dosing effective for maintaining visual acuity gains in patients with BRVO and CRVO

Mimi Liu; Pin-wen Wang; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):4163. doi:

ARVO Annual Meeting Abstract September 2016

Prevalence of drusen and conversion to neovascular age-related macular degeneration in the HARBOR study fellow eyes

Caroline R Baumal; Carlos Quezada Ruiz; Shamika Gune; Pin-wen Wang; Anne E Fung

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):4967. doi:

ARVO Annual Meeting Abstract September 2016

Pan-retinal photocoagulation for diabetic retinopathy: is it one and done?

Victor H Gonzalez; Pin-wen Wang; Carlos Quezada Ruiz; Anne E Fung

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):6355. doi:

ARVO Annual Meeting Abstract June 2015

Durability of diabetic retinopathy improvement and impact of delayed therapy with ranibizumab (RBZ) during the RIDE/RISE open-label extension (OLE)

Jennifer K Sun; Pin-wen Wang; Anne E. Fung

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3143. doi:

ARVO Annual Meeting Abstract June 2015

Baseline predictors of early visual acuity improvement in RVO patients treated with ranibizumab in the SHORE study

Mimi Liu; Pin-wen Wang; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5802. doi:

Advertisement